For more information

Dept. of Dermatology
Mail Code: L468R
Oregon Health & Science University
3181 SW Sam Jackson Park Rd.
Portland, OR 97239

Office: (503) 418-4273
Fax: (503) 418-4266

info(at)
montagnasymposium.org

Molly Kulesz-Martin, Ph.D.
Symposium Director

David Norris, M.D.
Jackie Bickenbach, Ph.D.
Symposium Director Emeriti

Looking for meeting photos and updates? Follow the Montagna Symposium on Facebook
Facebook

Continuing Medical Education - Certification is in process

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of OHSU School of Medicine and the PanAmerican Society for Pigment Cell Research. The OHSU School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit
OHSU School of Medicine designates this live activity for a maximum of 17.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience
Dermatologists, oncologists, rheumatologists, pathologists and other physicians treating patients with conditions that may be elucidated by presentation and discussion of current clinical and basic research relating to skin pigmentation

Learning Objectives
Through invited and accepted oral presentations, poster presentations, group debate, Q&A, and informal conversations, participants will interpret current research findings/approaches in melanocyte biology & chemistry and melanoma & vitiligo patient care and apply them, where appropriate, to their own research and practice.  At the conclusion of the meeting, participants will be able to 1) evaluate the use of different animal models for understanding melanoma and vitiligo pathogenesis; 2) view human melanocyte biology at the scale of the “human model system;” 3) review the role of stem cells and development in normal and disordered pigmentation;  4) associate immunological and microenvironmental processes with the development of melanoma and vitiligo; 5) recognize the relationship between genetics, early detection, and prevention of melanoma; 6) assess approaches to melanoma and vitiligo therapeutics that capitalize on cell signaling pathways; and 7) examine the effects of the photochemistry and toxicology of pigment cells on human health. Participants will be able to identify and engage with colleagues in dermatology, oncology, and related fields who are working toward cutting-edge translational solutions to current problems in healthcare and who are open to collaboration and/or consultation. This meeting is designed promote conversations and ignite new ideas and new connections; desired changes in learner behavior include forming new collaborations, developing new research projects, designing new clinical trials, and applying new therapies in a clinical setting.

Funding for this conference was made possible (in part) by (2 R13AR009431-53) and (1 R13AR07429-01) from the National Institute Of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and all cofunding support provided the National Institute on Aging (NIA) and the National Institute of Environmental Sciences (NIEHS). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.